Emphasis should be put on alkali rich porphyry outcropping area in the east of Bengge to explore the gold deposit of Himalaya epo...
寻找喜马拉雅期金矿床，重点应放在甭哥以东的富碱斑岩出露区。
Using epoetin (epo) has become the major treatment regimen for patients with cancer -, radiotherapy - and chemotherapy-related anemia.
应用促红细胞生成素(EPO)是目前治疗癌症及放、化疗相关性贫血的主要方法。
In particular, the epo shall keep confidential and shall not convey to others any confidential information contained in reports except as otherwise expressly permitted by the Licensee in writing.
特别是，欧洲专利局应当保守秘密，不得将报告中包含的任何机密信息转达给其他人，除非被许可方另有明确的书面许可。
Then in 2004 the EPO revoked the patent entirely.
最终，在2004年，欧洲专利局撤消了它的专利权。
All in all, 653 patients required EPO.
在所有的病人中，653个病人需要EPO治疗。
Methods EPO was determined with ELISA.
方法红细胞生成素测定采用酶联法。
Objective To find the detecting method of erythropoietin (EPO).
目的探索兴奋剂促红细胞生成素(EPO)的检测方法。
Research techniques on the preparation of EPO for injection use.
摸索制备注射用月见草油的小试工艺。
Erythropoietin (EPO) is widely used in clinical and basic studies.
红细胞生成素(EPO)在临床和基础研究中应用广泛。
EPO is a natural hormone that stimulates production of the Hb-containing red blood cells.
促红细胞生成素是一种天然的激素，可以促进含血红蛋白的红细胞的生成。
Erythropoietin (EPO) is a kind of endogenesis cell factor which was excreted by the kidney.
促红细胞生成素(EPO)是由肾脏分泌的内源性细胞因子。
Finally, the EPO will take a decision based on facts and arguments presented by both sides.
最终，欧洲专利局会根据双方呈现的事实与论据做最后的裁定。
The EPO shall take all reasonable steps to avoid the inclusion of such non-conforming data.
欧洲专利局应当采取一切合理的措施，避免包含上述不符合要求的数据。
Conclusion Depressed functions of neutrophils in uremic patients were improved by EPO treatment.
结论尿毒症患者中性粒细胞功能受损，接受EPO治疗后，其功能得到改善。
All data carriers will be supplied by the EPO to the Licensee in the format specified in Annex a.
所有数据载体将由欧洲专利局按照附件A指定的格式提供给被许可方。
Objective: To investigate the role of EPO in the pathogenesis of high altitude polycythemia (HAPC).
目的：探讨EPO在高原红细胞增多症发病机制中的作用。
The EPO has its headquarters in Munich, a branch in The Hague, and sub-offices in Berlin and Vienna.
欧洲专利局总部设在慕尼黑，一个分支在海牙，分办事处在柏林和维也纳。
Leptin was positively correlated with BMI in HD patients, and EPO therapy can make the relationship disappear.
血液透析病人血瘦素与BMI呈正相关，但重组人促红细胞生成素治疗可使两者相关性消失。
Aim To study the effect of high C-reactive protein (CRP) on dose of erythropoietin (EPO) in hemodialysis patients.
目的研究高血清c反应蛋白(CRP)对血液透析患者促红细胞生成素(EPO)治疗效果的影响。
Objective: To investigate in vitro release characteristics of collagen double layer minipellet of erythropoietin(EPO).
前言： 目的：对红细胞生成素胶原蛋白双层微条的体外释放特性进行研究。
Objective To study the inhibitive effect of evening primrose oil (EPO) on cultured cardiomyocytes hypertrophy in rats.
目的探讨宁夏产月见草油对体外培养大鼠心肌细胞肥大的抑制作用。
The IOC Medical Commission has approved a test to detect the use of the banned synthetic hormone erythropoietin, or EPO.
国际奥委会药物委员会已经通过了一项测试来检测违禁使用合成激素红细胞生成素（简称EPO）的情况。
Renal anemia is mostly caused by insufficient EPO produced by kidney, which mainly required to be treated with external EPO.
肾性贫血主要是由于肾脏产生红细胞生成素(EPO)不足而引起，这类贫血主要靠补充外源性EPO进行治疗。
Studies have found that EPO receptor is widely distributed in a variety of non-hematopoietic tissue, including myocardial tissue.
研究发现EPO受体广泛分布于各种非造血组织，其中包括心脏组织。
The existing evidence on the early use of EPO-A in the acute phase of trauma patients management consists of only 14 publications.
关于促红细胞生成素- A (EPO - A)应用于创伤患者治疗急性期的现存临床证据仅14篇已发表文献。
OBJECTIVE: To investigate the effects of kidney tissue allograft transplantation on EPO gene expression in rats with renal anemia.
目的：观察肾组织移植对肾性贫血大鼠促红细胞生成素基因表达的影响。
As a result of today's decision, European Patent number 0904607, originally issued to UT, has been revoked by the EPO in its entirety.
根据今天的裁决，原授予得克萨斯大学的0904607号欧洲专利现已被欧洲专利局完全撤销。
Renal pathological changes were observed, and the expression of EPO in transplantation tissue was examined by Immunohistochemical method.
观察肾组织病理改变，用免疫组化方法检测EPO在移植物中的表达。
The Licensee is not permitted to copy an EPO data carrier using all data, data structure and software as sent to the Licensee by the EPO.
被许可方不得复制使用欧洲专利局送交被许可方的数据、数据结构和软件的欧洲专利局数据载体。
The Licensee is not permitted to copy an EPO data carrier using all data, data structure and software as sent to the Licensee by the EPO.
被许可方不得复制使用欧洲专利局送交被许可方的数据、数据结构和软件的欧洲专利局数据载体。
应用推荐